查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1599692

mRNA 治療市場：按類型、應用和最終用途 - 2025-2030 年全球預測

mRNA Therapeutics Market by Type (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines), Application (Infectious Diseases, Oncology, Rare Genetic Diseases), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年 mRNA 治療市場價值為 338.2 億美元，預計到 2024 年將達到 419.9 億美元，複合年成長率為 24.65%，到 2030 年將達到 1582 億美元。

mRNA療法是指利用傳訊RNA來引導細胞產生有助於治療或預防疾病的蛋白質。這個快速發展的領域正在利用人類細胞中蛋白質合成的自然過程來解決各種健康狀況，從像 COVID-19 這樣的感染疾病到像癌症這樣的非感染疾病。對 mRNA 療法的需求在於其快速開發、可擴展性和多功能性的潛力，這些已經在使用有效疫苗對 COVID-19 大流行的快速反應中得到了證明。主要應用和終端市場包括免疫、癌症免疫治療和罕見遺傳疾病，為個人化醫療提供了廣闊的前景。

主要市場統計
基準年[2023] 338.2億美元
預測年份 [2024] 419.9億美元
預測年份 [2030] 1,582億美元
複合年成長率（%） 24.65%

mRNA 療法的市場成長主要是由技術進步、公共和私人資金增加以及生物技術和製藥公司之間的策略聯盟所推動的。 mRNA 疫苗最近的成功激發了人們的興趣和投資，為將基於 mRNA 的療法擴展到感染疾病以外的領域提供了潛在機會。利用這些機會的建議包括投資強大的研發基礎設施、建立策略聯盟以及注重監管控制以促進市場進入。

阻礙市場開拓的挑戰包括高昂的開發成本、由於 mRNA 固有的不穩定性而導致的複雜的儲存和分配，以及證明長期安全性和有效性的監管障礙。此外，製造能力的限制和智慧財產權糾紛也是重大障礙。

創新和研究的目標應是最佳化 mRNA 穩定性和遞送系統，提高靶向特定細胞和組織的精確度，並降低製造成本。市場動態的特徵是快速的技術創新、激烈的競爭和高度動態的監管要求。與學術界和研究機構的合作可以提供寶貴的見解，並推動這一極具前景的領域的前瞻性策略。

市場動態：揭示快速發展的 mRNA 治療市場的關鍵市場洞察

供需的動態交互作用正在改變 mRNA 治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病和感染疾病的盛行率增加
    • 對癌症疫苗和治療的需求不斷成長
    • 對 mRNA 療法的需求激增以及政府對大規模定序計劃的舉措
  • 市場限制因素
    • 高研究成本和 mRNA 定量失敗的威脅
  • 市場機會
    • 生物技術研究與開發 (R&D)舉措的活性化以及醫療技術的進步
    • 透過強大的新產品系列開發個人化癌症治療方法
  • 市場問題
    • mRNA 治療的監管問題與策略

波特五力：引領 mRNA 治療市場的策略工具

波特的五力框架是了解 mRNA 治療市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解 mRNA 治療市場的外部影響

外部宏觀環境因素在塑造 mRNA 治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解 mRNA 治療市場的競爭格局

對 mRNA 治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：mRNA 治療市場供應商的績效評估

FPNV定位矩陣是評估mRNA治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製 mRNA 治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 mRNA 治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和感染疾病的發生率增加
      • 對癌症疫苗和治療的需求增加
      • 對 mRNA 療法的需求不斷成長，政府對大規模定序計劃的承諾不斷增加
    • 抑制因素
      • 高研究成本和 mRNA 定量失敗的威脅
    • 機會
      • 重大生物技術研發 (R&D)舉措與醫療技術進步
      • 透過強大的新產品系列開發個人化癌症治療方法
    • 任務
      • mRNA 治療的監管問題與策略
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 mRNA 治療市場：依類型

  • 介紹
  • 預防性疫苗
  • 治療
  • 治療性疫苗

第7章 mRNA 治療市場：依應用分類

  • 介紹
  • 感染疾病
  • 腫瘤學
  • 罕見遺傳疾病
  • 呼吸系統疾病

第 8 章 mRNA 治療市場：依最終用途分類

  • 介紹
  • 醫院/診所
  • 研究所

第9章美洲mRNA治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太mRNA治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲/中東/非洲mRNA治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abogen Biosciences
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics
  • AstraZeneca plc
  • BioNTech SE
  • CRISPR Therapeutics AG
  • Deep Genomics
  • Eli Lilly and Company
  • GSK plc
  • Laronde Inc.
  • Moderna, Inc.
  • Nutcracker Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Tracxn Technologies Limited
  • Translate Bio, Inc. by Sanofi SA
Product Code: MRR-205091A88BBD

The mRNA Therapeutics Market was valued at USD 33.82 billion in 2023, expected to reach USD 41.99 billion in 2024, and is projected to grow at a CAGR of 24.65%, to USD 158.20 billion by 2030.

mRNA therapeutics refers to the use of messenger RNA to instruct cells to produce proteins that can treat or prevent disease. This rapidly evolving field leverages the natural process of protein synthesis in human cells to address a variety of health conditions, ranging from infectious diseases, such as COVID-19, to non-communicable diseases like cancer. The necessity of mRNA therapeutics lies in its potential for rapid development, scalability, and versatility, which have already been demonstrated in the swift response to the COVID-19 pandemic with effective vaccines. The primary application and end-use scope encompass vaccinations, cancer immunotherapies, and rare genetic disorders, offering a promising outlook for personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 33.82 billion
Estimated Year [2024] USD 41.99 billion
Forecast Year [2030] USD 158.20 billion
CAGR (%) 24.65%

Market growth in mRNA therapeutics is significantly influenced by technological advancements, increased funding from public and private sectors, and strategic collaborations between biotech firms and pharmaceutical companies. The recent success of mRNA vaccines has spurred interest and investment, leading to potential opportunities in expanding mRNA-based treatments beyond infectious diseases. Recommendations to capitalize on these opportunities include investing in robust R&D infrastructures, forging strategic alliances, and focusing on regulatory pathways to facilitate market entry.

Challenges curbing market growth involve the high cost of development, storage and distribution complexities due to mRNA's inherent instability, and regulatory hurdles in proving long-term safety and efficacy. Additionally, manufacturing capacity constraints and intellectual property disputes present significant barriers.

Innovation and research should target optimization of mRNA stability and delivery systems, improvement in the precision of targeting specific cells or tissues, and reducing production costs. The nature of the mRNA therapeutics market is characterized by rapid technological changes, strong competition, and highly dynamic regulatory requirements. Collaborations with academia and research institutions can provide valuable insights and drive forward-thinking strategies in this highly promising field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Therapeutics Market

The mRNA Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of chronic and infectious diseases
    • Growing demand for cancer vaccines and treatments
    • Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
  • Market Restraints
    • High cost of research and threat of failure in quantification of mRNA
  • Market Opportunities
    • Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
    • Development of personalized therapeutics for cancer with strong pipeline of new products
  • Market Challenges
    • Regulatory concerns and strategies for mRNA therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Therapeutics Market

A detailed market share analysis in the mRNA Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Therapeutics Market

A strategic analysis of the mRNA Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abogen Biosciences, Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, AstraZeneca plc, BioNTech SE, CRISPR Therapeutics AG, Deep Genomics, Eli Lilly and Company, GSK plc, Laronde Inc., Moderna, Inc., Nutcracker Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Tracxn Technologies Limited, and Translate Bio, Inc. by Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the mRNA Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Prophylactic Vaccines, Therapeutic Drugs, and Therapeutic Vaccines.
  • Based on Application, market is studied across Infectious Diseases, Oncology, Rare Genetic Diseases, and Respiratory Diseases.
  • Based on End Use, market is studied across Hospitals & Clinics and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of chronic and infectious diseases
      • 5.1.1.2. Growing demand for cancer vaccines and treatments
      • 5.1.1.3. Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of research and threat of failure in quantification of mRNA
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
      • 5.1.3.2. Development of personalized therapeutics for cancer with strong pipeline of new products
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory concerns and strategies for mRNA therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. mRNA Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Prophylactic Vaccines
  • 6.3. Therapeutic Drugs
  • 6.4. Therapeutic Vaccines

7. mRNA Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Infectious Diseases
  • 7.3. Oncology
  • 7.4. Rare Genetic Diseases
  • 7.5. Respiratory Diseases

8. mRNA Therapeutics Market, by End Use

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Organizations

9. Americas mRNA Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific mRNA Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa mRNA Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abogen Biosciences
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Arcturus Therapeutics
  • 4. AstraZeneca plc
  • 5. BioNTech SE
  • 6. CRISPR Therapeutics AG
  • 7. Deep Genomics
  • 8. Eli Lilly and Company
  • 9. GSK plc
  • 10. Laronde Inc.
  • 11. Moderna, Inc.
  • 12. Nutcracker Therapeutics, Inc.
  • 13. Sangamo Therapeutics, Inc.
  • 14. Sarepta Therapeutics, Inc.
  • 15. Tracxn Technologies Limited
  • 16. Translate Bio, Inc. by Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. MRNA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 146. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023